Background-Some but not all studies have reported reduced rates of stent thrombosis (ST) with everolimus-eluting stents (EES) compared with other drug-eluting stents (DES). All of these studies were insufficiently powered to reliably detect differences in ST. We therefore performed a meta-analysis of randomized controlled trials comparing the risk of 2-year definite ST between EES and other DES. 
T he introduction of drug-eluting stents (DES) has transformed the landscape of percutaneous coronary intervention. Several randomized controlled trials (RCT), 1,2 observational studies, 3 and meta-analyses 4, 5 have consistently shown 40% to 70% reductions of angiographic restenosis and ischemia-driven target vessel revascularization with DES compared with bare metal stents. Following the US approval of sirolimuseluting stents (SESs; Cypher; Cordis Corp, Miami Lakes, FL) and paclitaxel-eluting stents (PES; Taxus; Boston Scientific, Natick, MA), concern was raised over the ongoing propensity of these devices for late stent thrombosis (ST). 6 A pooled analysis of RCT comparing PES or SES versus bare metal stent demonstrated that the rates of very late ST (beyond 1 year) were significantly increased with these first-generation DES, 5 and a large observational study enrolling Ͼ8000 patients documented an annual rate of very late ST with DES of 0.4% to 0.6% with no plateau evident with follow-up through 4 years. 7 Persistent inflammation, hypersensitivity reactions, delayed endothelial healing, strut fracture, late acquired malapposition, and neoatherosclerosis are proposed pathophysiological mechanisms associated with first-generation DES thrombosis. 8, 9 Editorial see p 332
These safety concerns prompted the development of newer DES, which use different stent design and delivery systems, novel biocompatible polymers, and new drugs compared with their predecessors. In the Xience V stent (Abbott Vascular, Santa Clara, CA, also distributed as the Promus stent, Boston Scientific), the antiproliferative drug (everolimus) is released from a thin layer of an inert and thromboresistant fluoropolymer coated on a thin-strut cobalt-chromium stent. In some (but not all) RCTs, this everolimus-eluting stent (EES) has resulted in significantly fewer ST episodes compared with PES, SES, or zotarolimus-eluting stents (ZES). However, none of these trials were individually powered to detect differences in ST, and it therefore remains unclear whether these findings are real or represent the play of chance. Because ST is an infrequent but catastrophic clinical event, 10 determining whether there are true differences in the risk of ST between DES has important clinical implications. Accordingly, we performed a meta-analysis of RCTs to investigate whether EES is associated with a different risk of ST than other DES.
WHAT IS KNOWN
• DES have significantly reduced the risk of restenosis and ischemia-driven target vessel revascularization.
• There is concern about the ongoing propensity of first-generation DES for late and very late stent thrombosis.
• Whether more recently developed DES improve safety is unknown.
WHAT THE STUDY ADDS
• This analysis provides evidence that the secondgeneration EES, which uses a different platform and polymer compared with first-and other secondgeneration DES, is associated with significantly lower rates of early, late, and 2-year definite stent thrombosis compared with pooled PES, SES, and the Resolute ZES.
• These findings may have practical implications in the care of patients undergoing percutaneous coronary intervention.
Methods

Objective, Definitions, and Study Design
To accrue maximal power to determine whether EES is associated with a reduced risk of ST than other DES, we identified and aggregated the clinical data from all published and publically presented RCTs in which EES was compared with other DES. The primary end point of this study was the 2-year rate of definite ST according to the Academic Research Consortium (ARC) criteria 11 in patients treated with EES versus pooled patients treated with other DES with interaction analysis performed to identify potential differences in the relative risk (RR) of ST between EES and different DES comparators. Secondary prespecified end points included the 2-year rates of ARC definite or probable ST (which is less specific for ST than angiographically confirmed definite ST) as well as the rates of early (Յ30 days), late (31 days to 1 year), and 1-year definite and definite/probable ST. Because few comparative studies with data beyond 2 years have been reported, outcomes were restricted to 2-year follow-up. Rates of ST reported at 9 months were pooled with those reported at 1 year if the 1-year data report was unavailable.
When multiple episodes of ST occurred in the same patient in different time periods, each was tabulated in the intervals in which they occurred, but each patient with ST was counted only once in the cumulative analysis of 1-year or 2-year ST.
Data Source and Study Selection
Relevant RCTs to include in this meta-analysis were searched through MEDLINE, the Cochrane database, the EMBASE database, www.tctmd.com, www.clinicaltrials.gov, www.clinicaltrialresults. org, www.cardiosource.com, and abstracts and presentations from major cardiovascular meetings using the key words randomized clinical trial, drug-eluting stent, everolimus-eluting stent, paclitaxeleluting stent, sirolimus-eluting stent, and zotarolimus-eluting stent.
No language, publication date, or publication status restrictions were imposed. The most updated or most inclusive data for a given study were chosen for abstraction. Internal validity of RCTs was assessed by evaluating concealment of allocation, blind adjudication of ST, and inclusion of all randomized patients in the analysis according to the intention-to-treat principle. Studies with no events in either arm were abstracted but not included in the meta-analysis. The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the article as written.
Statistical Analysis
RR and 95% CIs were used as the summary statistic. The pooled RR was calculated by using both fixed-effect (inverse variance weighted) and random-effect (DerSimonian and Laird) models. Possible interactions between the overall RR of ST and DES comparators were evaluated by comparing the RRs of EES versus individual DES comparators. Briefly, the interaction test was calculated using the log RR and their CI. The SE of each log RR was obtained by dividing the CI by 2ϫ1.96. The interaction was calculated by dividing the ratio of log RR between EES and any DES comparator by its SE. A detailed explanation of this method is provided by Altman and colleagues. 12 Results are expressed as RR ratios and 95% CI. Given the comparison of EES to 3 different comparator DES, adjustments for multiple comparisons were performed with the Bonferroni test with statistical significance reached at PϽ0.017. Between-study heterogeneity of effects was analyzed using the 2 and I 2 statistics. The possibility of publication bias was assessed by visual inspection of funnel plots and by Peter's test. Sensitivity analysis was performed by evaluating the influence of removing individual studies on the pooled RR. Statistical analyses were performed using Stata/SE 11.2 (StataCorp LP, College Station, TX).
Results
The flow diagram of the study is shown in online-only Data Supplement Figure I . Of 1632 potentially relevant articles initially screened, 37 studies comparing EES with other DES were identified. Among these 37 studies, 23 were excluded because they were not RCTs, 1 was excluded because it was a RCT comparing 2 EES with the same polymer but different metallic stent platforms, 13 and 2 were excluded because there were no episodes of ST throughout the duration of the study. 14, 15 Therefore, a total of 11 trials met the inclusion criteria and were included in the final meta-analysis. 16 -26 Five trials compared EES with PES (Taxus Express or Liberté platforms), 17,24 -27 5 trials compared EES with SES (Cypher), 16,19 -22 and 1 trial compared EES with ZES (Resolute platform; Medtronic, Santa Rosa, CA). 23 Main characteristics of the included trials appear in the Table. The major inclusion and exclusion criteria and internal validity assessment for each trial are reported in online-only Data Supplement Table I . The clinical characteristics of the patients enrolled in the RCTs included in the meta-analysis are reported in online-only Data Supplement Table II. All trials adjudicated ST according to the ARC criteria. The contribution of individual studies to the analyzed time periods for ST is shown in online-only Data Supplement Table III ; data from at least 11 934 randomized patients were available for analysis for each time interval.
Two-Year ST
Seven trials 16, 17, 20, [23] [24] [25] [26] Figure 1A and in online-only Data Supplement Table IV , the 2-year RR of definite ST for EES versus pooled PES, SES, and ZES was 0.38 (95% CI, 0.24 -0.59; PϽ0.0001) in both fixed-effect and random-effect models. The absolute risk difference in 2-year definite ST rates between EES and other DES was Ϫ0.6% with 123 patients needed to be treated with EES to avoid 1 episode of definite ST. Therefore, it is estimated that at 2-year follow-up, 8.1 (95% CI, 5.3-9.9) episodes of definite ST would be avoided per 1000 patients treated with EES rather than another DES. Similar results were apparent for the less specific end point of definite/ probable ST ( Figure 1B ; online-only Data Supplement Figure 3 and in online-only Data Supplement 
Late ST
As shown in Figure 4A -B and in online-only Data Supplement 
Interactions, Heterogeneity, and Sensitivity Analysis
The significant reduction of early, late, very late, cumulative 1-year, and cumulative 2-year definite ST observed with EES was consistent across all DES comparators (online-only Data Supplement Table VI) . However, a significant interaction was present between the RR reduction of definite/probable ST with EES versus PES compared with EES versus SES at 30 days (both for fixed-and random-effect models) and at 1 year (fixed-effect model only) but not at 2 years (online-only Data Supplement Table VI ) or during other intervals.
As shown in online-only Data Supplement Tables IV and VII, no significant heterogeneity was apparent across studies at any time point, there was no apparent systematic bias as assessed by funnel plots and Peter's test, and no individual study unduly influenced the primary effects estimate.
Discussion
The major findings of the present meta-analysis, drawn from 11 RCTs of EES versus other DES in 16 775 patients, are: (1) EES significantly reduced the risk of definite ST at 30 days, 1 year, and 2 years compared with pooled PES, SES, and ZES with no interaction apparent between the overall RR of definite ST and the individual DES comparators; and (2) a similar reduction of ST was apparent for EES compared with other DES by the broader definition of definite/probable ST but with a significant interaction noted between the RR reduction of definite/probable ST with EES versus PES compared with EES versus SES at 30 days and possibly at 1 year, although not at 2 years. Given the high rates of morbidity and mortality with ST, 10 the demonstration that EES is associated with a markedly lower risk of definite ST compared with pooled SES, PES, and ZES (a 72% relative reduction at 30 days and at 1 year and a 62% relative reduction at 2 years) has important clinical implications. Of note is the fact that EES compared with pooled DES significantly reduced definite ST not only at 2 years, but also separately during the early and late time periods. As many as 60% of all thrombotic episodes occur in the first 30 days after stent implantation; ST during this time interval has been associated with mechanical factors such as stent underexpansion or unrecognized intimal dissection and patient-related characteristics such as diabetes, renal dysfunction, or premature discontinuation of dual antiplatelet therapy. 8 -10 In contrast, late and very late ST have been more strongly associated with delayed endothelial healing, strut fracture, chronic hypersensitivity reactions, late acquired malapposition, and neoatherosclerosis, which are more frequently encountered with DES than bare metal stent. 9, 28 The fact that EES compared with other DES resulted in lower rates of definite ST in both the early as well as the late period (a finding that was independent of the comparator DES) is therefore of relevance when considering the potential mechanisms of this protective effect, which likely includes more rapid and complete endothelialization, 9 as well as differences in stent alloy and architecture, strut thickness, polymer characteristics, and antiproliferative drug type, dose, and release kinetics. Specifically, the thin (81 m), fracture-resistant cobalt-chromium stent struts of the EES design, the potentially thromboresistant fluorocopolymer, and the low polymer and drug load may contribute to the low rate of ST observed with EES. 29 In addition to reducing the rates of definite ST, EES compared with pooled DES reduced the 30-day, 1-year, and 2-year rates of definite or probable ST, which in addition to angiographically confirmed ST also includes unexplained deaths within 30 days after the procedure and acute myocardial infarction involving the target vessel territory without angiographic confirmation. By this less specific definition of ST, a significant interaction was present such that the reduction in ST with EES compared with PES was greater than that with EES compared with SES at 30 days and possibly at 1 year (fixed-effects model only) but not at 2 years. Prior studies have reported conflicting data regarding the relative safety and efficacy of SES versus PES 30, 31 and a greater degree of very late angiographic restenosis has been described with SES compared with PES. 32 Whether the greater reduction of definite/probable ST with EES compared with SES versus PES in the early and 1-year periods is real, represents differences in clinical trial methodology, and/or patient selection between the SES and PES trials considered in the present report cannot be answered with certainty. Moreover, our findings emphasize the relative importance of ST definitions, whose use will vary depending on whether the goal is for greater specificity (only definite ST) or greater sensitivity (definite/probable ST). It is likely that the more liberal ARC definite/probable definition of ST includes events which are not truly ST, thus reducing the level of certainty and diluting possible differences existing between different stents. For this reason, our primary end point was prespecified as the more conservative but more specific ARC definition of definite ST. Also of note, the relative reduction in definite ST with EES was independent of comparator DES at all time periods.
Our data are consistent with a recent meta-analysis reporting significantly lower rates of definite/probable ST with EES compared with other DES after a median follow-up of 21.7 months. 33 The present study significantly extends the findings from this prior report. Unique aspects of our study include the analysis of definite as well as definite or probable ST; separate evaluation of early and late ST; and the assessment of cumulative ST to 2 years. Our report demonstrates that a comparative examination between stents may indeed depend on the definition of the end points (with EES reducing ST to a greater degree using the more specific definition of definite ST than the less explicit definition of definite or probable ST) and that differences in ST between DES are not restricted to the late period after implantation but occur also in the early period. This observation suggests that optimizing DES components and performance is essential to minimize early as well as late ST, an important finding because early ST is more frequent than late ST.
This report has several limitations. Results were analyzed on aggregate data and therefore we could not assess whether all baseline characteristics were balanced between the groups (although for the most part they were within each RCT). Similarly, we could not assess whether the magnitude of the reduction in ST with EES compared with pooled DES was greater or lesser in specific subgroups. Follow-up was restricted to 2 years, and therefore whether the observed differences remain constant, increase, or diminish at longerterm follow-up is unknown. It should be noted that the present results demonstrate that EES is associated with a reduced risk of ST relative to a pooled comparator group of PES, SES, and ZES rather than to any specific DES. Interaction testing is inherently underpowered and thus we cannot determine whether the reduction in definite ST with EES compared with SES is as great as with EES compared with PES, especially at 2 years, when a significant difference in definite ST was apparent for EES versus PES, but not for EES versus SES. Only 1 study comparing EES versus ZES (Resolute platform) has been performed, which although large (nϭ2292) limits the statistical power of this analysis, and no head-to-head studies have compared EES versus ZES (Endeavor platform). Finally, the susceptibility to ST is only 1 component of the overall safety and efficacy profile of DES; other characteristics of device performance and outcomes should also be considered in individual patients when making stent selection decision.
In conclusion, in this large comparative meta-analysis from 11 randomized trials including 16 775 patients, EES significantly reduced the risk of early (30-day), late (31-day to 1-year), cumulative 1-year, very late (1-to 2-year), and cumulative 2-year definite ST compared with a pooled group of PES, SES, or ZES with no significant interactions apparent between the relative reduction of ST with EES and the individual DES comparators.
